î
îŒ
î
Novo Nordisk A/S
NVO52.400USD
-0.160-0.30%
çµå€Â 12/26, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
176.28Bæ䟡ç·é¡
15.18çŽè¿12ã¶æPER
î
詳现æ å ± Novo Nordisk A/S äŒæ¥å
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Novo Nordisk A/Sã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãNVO
äŒç€ŸåNovo Nordisk A/S
äžå Žæ¥May 17, 1974
æé«çµå¶è²¬ä»»è
ãCEOãDoustdar (Maziar Mike)
åŸæ¥å¡æ°76302
蚌åžçš®é¡Depository Receipt
決ç®ææ«May 17
æ¬ç€Ÿæåšå°Novo Alle 1
éœåžBAGSVAERD
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœDenmark
éµäŸ¿çªå·2880
é»è©±çªå·4544448888
ãŠã§ããµã€ãhttps://www.novonordisk.com/
äŒæ¥ã³ãŒãNVO
äžå Žæ¥May 17, 1974
æé«çµå¶è²¬ä»»è
ãCEOãDoustdar (Maziar Mike)
Novo Nordisk A/Sã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Cees de Jong
Dr. Cees de Jong
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Tania Sabroe
Ms. Tania Sabroe
Executive Vice President - People, Organisation & Corporate Affairs
Executive Vice President - People, Organisation & Corporate Affairs
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research & Development
Executive Vice President, Chief Scientific Officer, Research & Development
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Cees de Jong
Dr. Cees de Jong
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
åçå èš³
é貚: USDæŽæ°æå»: Mon, Oct 6
é貚: USDæŽæ°æå»: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
ä»ã®
1.04B
8.92%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
USA
6.53B
55.90%
Canada
2.50B
21.40%
Emerging Markets
1.15B
9.82%
APAC
852.83M
7.31%
Region China
651.28M
5.58%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
ä»ã®
1.04B
8.92%
æ ªäž»
æŽæ°æå»: Sun, Nov 16
æŽæ°æå»: Sun, Nov 16
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
ä»ã®
97.91%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
ä»ã®
97.91%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
4.66%
Investment Advisor/Hedge Fund
2.41%
Research Firm
0.92%
Hedge Fund
0.38%
Pension Fund
0.33%
Bank and Trust
0.20%
Insurance Company
0.19%
Family Office
0.02%
Family Office
0.02%
ä»ã®
90.87%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
2793
305.60M
9.08%
-33.91M
2025Q2
2754
330.35M
9.82%
-31.19M
2025Q1
2769
336.08M
9.99%
-21.71M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
2023Q2
1692
293.83M
8.50%
+768.69K
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Capital International Investors
11.62M
0.35%
+2.11M
+22.18%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
12.58M
0.37%
+187.79K
+1.52%
Jun 30, 2025
Fidelity Management & Research Company LLC
12.93M
0.38%
+3.95M
+44.01%
Jun 30, 2025
Fisher Investments
11.00M
0.33%
-870.32K
-7.33%
Jun 30, 2025
Folketrygdfondet
10.09M
0.3%
+572.63K
+6.01%
Jun 30, 2025
Managed Account Advisors LLC
8.81M
0.26%
+195.59K
+2.27%
Jun 30, 2025
Fayez Sarofim & Co.
10.50M
0.31%
-708.84K
-6.32%
Jun 30, 2025
Everett Harris & Co.
6.39M
0.19%
-13.84K
-0.22%
Jun 30, 2025
Parametric Portfolio Associates LLC
6.23M
0.19%
+587.70K
+10.42%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
Roundhill GLP-1 & Weight Loss ETF
15.04%
VanEck Pharmaceutical ETF
14.55%
Amplify Weight Loss Drug & Treatment ETF
9.51%
The Opal International Dividend Income ETF
3.79%
TrueShares Low Volatility Equity Income ETF
3.21%
First Trust WCM International Equity ETF
2.68%
Invesco International Dividend Achievers ETF
1.8%
Putnam Focused Large Cap Value ETF
1.16%
SP Funds S&P World (ex-US) ETF
1.05%
ActivePassive International Equity ETF
0.95%
詳现ãèŠã
Roundhill GLP-1 & Weight Loss ETF
æ¯ç15.04%
VanEck Pharmaceutical ETF
æ¯ç14.55%
Amplify Weight Loss Drug & Treatment ETF
æ¯ç9.51%
The Opal International Dividend Income ETF
æ¯ç3.79%
TrueShares Low Volatility Equity Income ETF
æ¯ç3.21%
First Trust WCM International Equity ETF
æ¯ç2.68%
Invesco International Dividend Achievers ETF
æ¯ç1.8%
Putnam Focused Large Cap Value ETF
æ¯ç1.16%
SP Funds S&P World (ex-US) ETF
æ¯ç1.05%
ActivePassive International Equity ETF
æ¯ç0.95%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
21.09B
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
Aug 06, 2025
NVO.NB Interim Cash Dividend of gross USD 0.58432 paid on Aug 26, 2025 going ex on Aug 18, 2025
Aug 18, 2025
Aug 26, 2025
Aug 18, 2025
Feb 06, 2025
NVO.NB Final Cash Dividend of gross USD 1.142561 paid on Apr 08, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Apr 08, 2025
Mar 31, 2025
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Interim Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Final Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Interim Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Interim Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Final Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
詳现ãèŠã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
Aug 14, 2023
Split
1â2
æ¥ä»
çš®é¡
æ¯ç
Aug 14, 2023
Split
1â2
ãããã質å
Novo Nordisk A/Sã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îNovo Nordisk A/Sã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
Capital International Investorsã¯11.62Mæ ªãä¿æããŠãããããã¯å šäœã®0.35%ã«çžåœããŸãã
Loomis, Sayles & Company, L.P.ã¯12.58Mæ ªãä¿æããŠãããããã¯å šäœã®0.37%ã«çžåœããŸãã
Fidelity Management & Research Company LLCã¯12.93Mæ ªãä¿æããŠãããããã¯å šäœã®0.38%ã«çžåœããŸãã
Fisher Investmentsã¯11.00Mæ ªãä¿æããŠãããããã¯å šäœã®0.33%ã«çžåœããŸãã
Folketrygdfondetã¯10.09Mæ ªãä¿æããŠãããããã¯å šäœã®0.30%ã«çžåœããŸãã
Capital International Investorsã¯11.62Mæ ªãä¿æããŠãããããã¯å šäœã®0.35%ã«çžåœããŸãã
Loomis, Sayles & Company, L.P.ã¯12.58Mæ ªãä¿æããŠãããããã¯å šäœã®0.37%ã«çžåœããŸãã
Fidelity Management & Research Company LLCã¯12.93Mæ ªãä¿æããŠãããããã¯å šäœã®0.38%ã«çžåœããŸãã
Fisher Investmentsã¯11.00Mæ ªãä¿æããŠãããããã¯å šäœã®0.33%ã«çžåœããŸãã
Folketrygdfondetã¯10.09Mæ ªãä¿æããŠãããããã¯å šäœã®0.30%ã«çžåœããŸãã
Novo Nordisk A/Sã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îNovo Nordisk A/Sã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
Capital International Investors
Loomis, Sayles & Company, L.P.
Putnam Investment Management, L.L.C.
Capital International Investors
Loomis, Sayles & Company, L.P.
Putnam Investment Management, L.L.C.
Novo Nordisk A/SïŒNVOïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãNovo Nordisk A/Sã®æ ªåŒãä¿æããŠããæ©é¢ã¯2793瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ305.60Mã§ãå
šäœã®9.08%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-0.74%å¢å ããŠããŸãã
Novo Nordisk A/Sã®æ倧ã®åçæºã¯äœã§ããïŒ
îFY2025Q2ã«ãããŠãTotal GLP-1éšéãNovo Nordisk A/Sã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯5.83Bã§ãå
šåçã®49.92%ãå ããŠããŸãã
